FDA Signals CardiAMP PMA Path Could Propel BioCardia Toward Market
The FDA meeting minutes suggest CardiAMP Heart Failure II trial may support PMA, a potential catalyst for BioCardia's growth. After a year of declines, BCDA shares rallied around $1.20, with momentum above multiple moving averages. Short-term resistance sits near $1.50, with support near $1.00.
View signal analysis